{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:16:17Z","timestamp":1773080177334,"version":"3.50.1"},"reference-count":100,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Rio Hortega Grant from Instituto de Salud Carlos III","award":["CM21\/00067"],"award-info":[{"award-number":["CM21\/00067"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>The eradication of the hepatitis C virus (HCV) has revolutionized the hepatology paradigm, halting the progression of advanced liver disease in patients with chronic infection and reducing the risk of hepatocarcinoma. In addition, treatment with direct-acting antivirals can reverse the lipid and carbohydrate abnormalities described in HCV patients. Although HCV eradication may reduce the overall risk of vascular events, it is uncertain whether altered lipid profiles increase the risk of cerebrovascular disease in certain patients. We have conducted a review on HCV and lipid and carbohydrate metabolism, as well as new scientific advances, following the advent of direct-acting antivirals.<\/jats:p>","DOI":"10.3390\/pathogens13040278","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T12:40:11Z","timestamp":1711370411000},"page":"278","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lipid Profile and Cardiovascular Risk Modification after Hepatitis C Virus Eradication"],"prefix":"10.3390","volume":"13","author":[{"given":"Andrea","family":"Pascual-Oliver","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6883-8940","authenticated-orcid":false,"given":"Diego","family":"Casas-Deza","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain"},{"name":"Adipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, University Hospital Miguel Servet, 50009 Zaragoza, Spain"},{"name":"Instituto Aragones de Ciencias de la Salud (IACS), 50009 Zaragoza, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria (IIS) Aragon, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Yag\u00fce-Caballero","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain"},{"name":"Adipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, University Hospital Miguel Servet, 50009 Zaragoza, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria (IIS) Aragon, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8982-3737","authenticated-orcid":false,"given":"Jose M.","family":"Arbones-Mainar","sequence":"additional","affiliation":[{"name":"Adipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, University Hospital Miguel Servet, 50009 Zaragoza, Spain"},{"name":"Instituto Aragones de Ciencias de la Salud (IACS), 50009 Zaragoza, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria (IIS) Aragon, 50009 Zaragoza, Spain"},{"name":"CIBER Fisiopatolog\u00eda Obesidad y Nutrici\u00f3n (CIBERObn), Instituto Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4016-2165","authenticated-orcid":false,"given":"Vanesa","family":"Bernal-Monterde","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain"},{"name":"Adipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, University Hospital Miguel Servet, 50009 Zaragoza, Spain"},{"name":"Instituto Aragones de Ciencias de la Salud (IACS), 50009 Zaragoza, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria (IIS) Aragon, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"The origin of hepatitis C virus","volume":"369","author":"Simmonds","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/cid\/ciu643","article-title":"Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006\u20132012","volume":"59","author":"Suryaprasad","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/CMR.13.2.223","article-title":"Clinical significance of hepatitis C virus genotypes","volume":"13","author":"Zein","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_4","unstructured":"WHO (2017). Global Hepatitis Report 2017, World Health Organization."},{"key":"ref_5","unstructured":"Polaris Observatory HCV Collaborators (2022). Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study. The lancet. Gastroenterol. Hepatol., 7, 396\u2013415."},{"key":"ref_6","first-page":"1","article-title":"Sexually Transmitted Diseases Treatment Guidelines","volume":"64","author":"Frieden","year":"2015","journal-title":"Morb. Mortal Wkly Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.1073\/pnas.1307527110","article-title":"Ultrastructural analysis of hepatitis C virus particles","volume":"110","author":"Catanese","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/v6031149","article-title":"Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion","volume":"6","author":"Vieyres","year":"2014","journal-title":"Viruses"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1128\/JVI.76.14.6919-6928.2002","article-title":"Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles","volume":"76","author":"Deforges","year":"2002","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tim.2010.11.005","article-title":"Assembly of infectious hepatitis C virus particles","volume":"19","author":"Bartenschlager","year":"2011","journal-title":"Trends Microbiol."},{"key":"ref_11","first-page":"199","article-title":"Virion assembly and release","volume":"369","author":"Lindenbach","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81","volume":"282","author":"Pileri","year":"1998","journal-title":"Science"},{"key":"ref_13","first-page":"167","article-title":"Hepatitis C virus RNA replication","volume":"369","author":"Lohmann","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1099\/vir.0.022186-0","article-title":"Ultrastructural and biochemical analyses of hepatitis C virus-associated host cell membranes","volume":"91","author":"Ferraris","year":"2010","journal-title":"J. Gen. Virol."},{"key":"ref_15","unstructured":"Paul, D., Hoppe, S., Saher, G., Krijnse-Locker, J., and Bartenschlager, R. (2024, January 10). Morphological and Biochemical Characterization of the Membranous Hepatitis C Virus Replication Compartment. Available online: http:\/\/jvi.asm.org\/."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Diamond, D.L., Syder, A.J., Jacobs, J.M., Sorensen, C.M., Walters, K.A., Proll, S.C., McDermott, J.E., Gritsenko, M.A., Zhang, Q., and Zhao, R. (2010). Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000719"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1128\/JVI.01565-07","article-title":"Visualization of Double-Stranded RNA in Cells Supporting Hepatitis C Virus RNA Replication","volume":"82","author":"Boulant","year":"2008","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/ncb1631","article-title":"The lipid droplet is an important organelle for hepatitis C virus production","volume":"9","author":"Miyanari","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0092-8674(00)81432-4","article-title":"Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha","volume":"93","author":"Peet","year":"1998","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1161\/01.CIR.0000146333.20727.2B","article-title":"Cellular physiology of cholesterol efflux in vascular endothelial cells","volume":"110","author":"Denis","year":"2004","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ecl.2022.02.008","article-title":"Lipid and Lipoprotein Metabolism","volume":"51","author":"Feingold","year":"2022","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10025","DOI":"10.1021\/acs.nanolett.2c03741","article-title":"The Extent to Which Lipid Nanoparticles Require Apolipoprotein E and Low-Density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid Structure","volume":"22","author":"Paunovska","year":"2022","journal-title":"Nano Lett."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gugliucci, A. (2023). Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134399"},{"key":"ref_24","unstructured":"Wang, N., Silver, D.L., Costet, P., and Tall, A.R. (2024, January 11). Specific Binding of ApoA-I, Enhanced Cholesterol Efflux, and Altered Plasma Membrane Morphology in Cells Expressing ABC1*. Available online: http:\/\/www.jbc.org."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fphys.2015.00061","article-title":"The pathophysiology of intestinal lipoprotein production","volume":"6","author":"Giammanco","year":"2015","journal-title":"Front. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1093\/eurheartj\/suw009","article-title":"Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia","volume":"18","author":"Ferrari","year":"2016","journal-title":"Eur. Heart J. Suppl. J. Eur. Soc. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1373\/clinchem.2010.155333","article-title":"HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events","volume":"57","author":"Rosenson","year":"2011","journal-title":"Clin. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-26","article-title":"Residual macrovascular risk in 2013: What have we learned?","volume":"13","author":"Fruchart","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3132\/dvdr.2008.046","article-title":"The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in dyslipidaemic patient","volume":"5","author":"Fruchart","year":"2008","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10557-013-6477-6","article-title":"Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values","volume":"27","author":"Rosenson","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterolrich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: A triumph of simplicity","volume":"27","author":"Williams","year":"2016","journal-title":"Curr Opin Lipidol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.arteri.2020.04.004","article-title":"Documento de consenso de un grupo de expertos de la Sociedad Espa\u00f1ola de Arteriosclerosis (SEA) sobre el uso cl\u00ednico de la resonancia magn\u00e9tica nuclear en el estudio del metabolismo lipoproteico (Liposcale)","volume":"32","author":"Masana","year":"2020","journal-title":"Cl\u00ednica Investig. Arterioscler."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jacl.2011.02.001","article-title":"Clinical implications of discordance between low-density lipoprotein cholesterol and particle number","volume":"5","author":"Otvos","year":"2011","journal-title":"J. Clin. Lipidol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1161\/CIRCULATIONAHA.115.016857","article-title":"Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial","volume":"132","author":"Mora","year":"2015","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Bermudez-Lopez, M., Perpi\u00f1an, H., Amigo, N., Castro, E., Alonso, N., Mauricio, D., Fernandez, E., and Valdivieso, J.M. (2023, January 10). Advanced Lipoprotein Parameters Could Better Explain Atheromatosis in Non-Diabetic Chronic Kidney Disease Patients. Available online: https:\/\/academic.oup.com\/ckj\/article\/14\/12\/2591\/6316255.","DOI":"10.1093\/ckj\/sfab113"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.amjcard.2016.03.040","article-title":"Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients with Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA])","volume":"117","author":"Tehrani","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MED.0000000000000389","article-title":"Discordance between lipoprotein particle number and cholesterol content: An update","volume":"25","author":"Cantey","year":"2018","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.7326\/0003-4819-123-8-199510150-00008","article-title":"Hepatitis C: A multifaceted disease-Review of extrahepatic manifestations","volume":"123","author":"Gumber","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S1590-8658(07)80009-0","article-title":"Hepatitis C virus lymphotropism: Lessons from a decade of studies","volume":"39","author":"Zignego","year":"2007","journal-title":"Dig. Liver Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/mco2.15","article-title":"De novo lipogenesis is elicited dramatically in human hepatocellular carcinoma especially in hepatitis C virus-induced hepatocellular carcinoma","volume":"1","author":"Li","year":"2020","journal-title":"MedComm"},{"key":"ref_42","unstructured":"Huang, H., Kang, R., and Zhao, Z. (2023, December 29). Is Hepatitis C Associated with Atherosclerotic Burden? A Systematic Review and Meta-Analysis. Available online: www.plosone.org."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clinre.2016.09.008","article-title":"Hepatitis C virus and atherosclerosis: A legacy after virologic cure?","volume":"41","author":"Bassendine","year":"2017","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2169\/internalmedicine.1514-18","article-title":"Carotid Intima-media Thickness and Small Dense Low-density Lipoprotein Cholesterol Increase after One Year of Treatment with Direct-acting Antivirals in Patients with Hepatitis C Virus Infection","volume":"58","author":"Ichikawa","year":"2019","journal-title":"Intern Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6150861","DOI":"10.1155\/2018\/6150861","article-title":"Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy","volume":"2018","author":"Drazilova","year":"2018","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/14787210.2018.1544492","article-title":"Updates in the management and treatment of HCV genotype 3, what are the remaining challenges?","volume":"16","author":"Huang","year":"2018","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40265-016-0685-x","article-title":"Genotype 3 Infection: The Last Stand of Hepatitis C Virus","volume":"77","author":"Chan","year":"2017","journal-title":"Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1478-3231.2008.01952.x","article-title":"Hepatitis C, insulin resistance and diabetes: Clinical and pathogenic data","volume":"29","author":"Serfaty","year":"2009","journal-title":"Liver Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jgh.12313","article-title":"Chronic hepatitis C infection is associated with insulin resistance and lipid profiles","volume":"30","author":"Dai","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3748\/wjg.v23.i9.1697","article-title":"Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review","volume":"23","author":"Desbois","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6095097","DOI":"10.1155\/2018\/6095097","article-title":"Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals","volume":"2018","author":"Drazilova","year":"2018","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2003.11.056","article-title":"Hepatitis C Virus Infection and Diabetes: Direct Involvement of the Virus in the Development of Insulin Resistance","volume":"126","author":"Shintani","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/gut.2010.236158","article-title":"Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2\/3","volume":"61","author":"Thompson","year":"2012","journal-title":"Gut"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","article-title":"Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients","volume":"128","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_55","first-page":"1027","article-title":"Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C","volume":"39","author":"Li","year":"2019","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_56","first-page":"713","article-title":"Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals","volume":"4","author":"Nevola","year":"2020","journal-title":"JGH Open Open Access J. Gastroenterol. Hepatol."},{"key":"ref_57","unstructured":"Arase, Y., Suzuki, F., Suzuki, Y., Akuta, N., Kobayashi, M., Kawamura, Y., Yatsuji, H., Sezaki, H., Hosaka, T., and Hirakawa, M. (2024, January 20). Sustained Virological Response Reduces Incidence of Onset of Type 2 Diabetes in Chronic Hepatitis C. Available online: https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/10.1002\/hep.22703."},{"key":"ref_58","first-page":"7629318","article-title":"Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C Virus","volume":"2016","author":"Voulgaris","year":"2016","journal-title":"Hepat. Res. Treat."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S1590-8658(07)80012-0","article-title":"HCV infection facilitates asymptomatic carotid atherosclerosis: Preliminary report of HCV RNA localization in human carotid plaques","volume":"39","author":"Boddi","year":"2007","journal-title":"Dig. Liver Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.3748\/wjg.v20.i13.3410","article-title":"Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms","volume":"20","author":"Adinolfi","year":"2014","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2018.01.007","article-title":"Comparison of cardiovascular outcomes and all-cause mortality in patients with chronic hepatitis B and C: A 13-year nationwide population-based study in Asia","volume":"269","author":"Wu","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2012.07.045","article-title":"Myocardial injury in patients with chronic hepatitis C infection","volume":"58","author":"Maruyama","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcv.2017.01.003","article-title":"Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients","volume":"88","author":"Cid","year":"2017","journal-title":"J. Clin. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/1060028018766507","article-title":"Incidence of Drug Interactions Identified by Clinical Pharmacists in Veterans Initiating Treatment for Chronic Hepatitis C Infection","volume":"52","author":"Ottman","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/tcmj.tcmj_247_19","article-title":"Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C","volume":"32","author":"Kuo","year":"2020","journal-title":"Tzu Chi Med. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.27424","article-title":"Effect of Sofosbuvir and Ribavirin Treatment on Peripheral and Hepatic Lipid Metabolism in Chronic HCV, Genotype-1 Infected Patients","volume":"61","author":"Meissner","year":"2015","journal-title":"Hepatology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"E203","DOI":"10.1111\/hepr.12970","article-title":"Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus","volume":"48","author":"Inoue","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3851\/IMP3094","article-title":"Effect of Antiviral Therapy for HCV on Lipid Levels","volume":"22","author":"Mauss","year":"2017","journal-title":"Antivir. Ther."},{"key":"ref_69","first-page":"1557","article-title":"Hepatitis C eradication with Sofosbuvir Leads to Significant Metabolic Changes","volume":"8","author":"Morales","year":"2016","journal-title":"Retrosp. Cohort Study"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/gutjnl-2017-313832","article-title":"Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir\/elbasvir or ledipasvir\/sofosbuvir treatment against chronic HCV infection","volume":"67","author":"Sun","year":"2018","journal-title":"Gut"},{"key":"ref_71","unstructured":"Girona, J., Amig\u00f3, N., Ibarretxe, D., Plana, N., Rodr\u00edguez-Borjabad, C., Heras, M., Ferr\u00e9, R., Gil, M., Correig, X., and Masana, L. (2024, January 25). HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk. Available online: www.mdpi.com\/journal\/ijms."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1099\/vir.0.032706-0","article-title":"Modulation of hepatitis C virus replication by iron and hepcidin in Huh7 hepatocytes","volume":"92","author":"Bartolomei","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0168-8278(01)00143-X","article-title":"Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C","volume":"35","author":"Petit","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jhep.2008.03.016","article-title":"Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study","volume":"49","author":"Dai","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_75","unstructured":"Kim, A.Y. (2023, December 12). Clinical Infectious Diseases AASLD-IDSA HCV Guidance Panel a. Available online: www.HCVGuidelines.org."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5604\/01.3001.0010.7536","article-title":"Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment","volume":"17","author":"Gitto","year":"2018","journal-title":"Ann. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/kjm2.12275","article-title":"Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication","volume":"36","author":"Huang","year":"2020","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Casas-Deza, D., Mart\u00ednez-Sapi\u00f1a, A., Espina, S., Garcia-Rodriguez, B., Fernandez-Bonilla, E.M., Sanz-Paris, A., Gonzalez-Irazabal, Y., Bernal-Monterde, V., and Arbones-Mainar, J.M. (2022). Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Na\u00efve Patients without History of Cardiovascular Disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11144049"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5009\/gnl17179","article-title":"Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b","volume":"12","author":"Chida","year":"2018","journal-title":"Gut Liver"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.3748\/wjg.v23.i13.2355","article-title":"Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b","volume":"23","author":"Endo","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/infdis\/jix517","article-title":"No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients with and without HIV","volume":"217","author":"Chaudhury","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1089\/aid.2015.0170","article-title":"Interferon-Free Treatment of Hepatitis C Virus in HIV\/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration","volume":"32","author":"Townsend","year":"2016","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/lt.25060","article-title":"Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients","volume":"24","author":"Beig","year":"2018","journal-title":"Liver Transpl."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/00365521.2018.1473486","article-title":"Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication comparison of the new direct-acting antiviral agents with the old regimens","volume":"53","author":"Carvalho","year":"2018","journal-title":"Scand J Gastroenterol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1435124","DOI":"10.1080\/19932820.2018.1435124","article-title":"Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs","volume":"13","author":"Soliman","year":"2018","journal-title":"Libyan J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Gonzalez-Colominas, E., Batlle, M., Monge-Escartin, I., Duran, X., Viu, A., de Antonio-Cusco, M., Grau, S., Bessa, X., and Carri\u00f3n, J.A. (2020). Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: Follow-up data 2 years after the sustained virological response. Eur. J. Gastroenterol. Hepatol.","DOI":"10.1097\/MEG.0000000000001714"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Doyle, M.A., Galanakis, C., Mulvihill, E., Crawley, A., and Cooper, C.L. (2019). Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters. Cells, 8.","DOI":"10.3390\/cells8030252"},{"key":"ref_88","first-page":"156","article-title":"Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving Daclatasvir\/Asunaprevir","volume":"10","author":"Ichikawa","year":"2019","journal-title":"Biomed. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1038\/s41598-018-26293-9","article-title":"Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter","volume":"8","author":"Shimizu","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41598-018-37829-4","article-title":"Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients","volume":"9","author":"Cheng","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12664-019-00935-w","article-title":"Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients","volume":"38","author":"Jain","year":"2019","journal-title":"Indian J. Gastroenterol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2015.09.007","article-title":"Hepatitis C Virus Infection Is Associated with Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies","volume":"150","author":"Petta","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2023.05.003","article-title":"Triglyceride-rich lipoproteins and insulin resistance in patients with chronic hepatitis C receiving direct-acting antivirals","volume":"375","author":"Espina","year":"2023","journal-title":"Atherosclerosis"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Hashimoto, S., Yatsuhashi, H., Abiru, S., Yamasaki, K., Komori, A., Nagaoka, S., Saeki, A., Uchida, S., Bekki, S., and Kugiyama, Y. (2016). Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163644"},{"key":"ref_95","unstructured":"Corey, K.E., Kane, E., Munroe, C., Barlow, L.L., Zheng, H., and Chung, R.T. (2024, January 13). Hepatitis C Virus Infection and Its Clearance Alter Circulating Lipids: Implications for Long-Term Follow-Up. Available online: https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/10.1002\/hep.23219."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1053\/j.gastro.2018.11.022","article-title":"Direct-Acting Antiviral Therapy for HCV Infection Is Associated with a Reduced Risk of Cardiovascular Disease Events","volume":"156","author":"Butt","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gutjnl-2017-313983","article-title":"The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection","volume":"67","author":"Mahale","year":"2018","journal-title":"Gut"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Daskalopoulou, S.S., Delaney, J.A.C., Filion, K.B., Brophy, J.M., Mayo, N.E., and Suissa, S. (2024, January 24). Discontinuation of Statin Therapy Following an Acute Myocardial Infarction: A Population-Based Study. Available online: https:\/\/academic.oup.com\/eurheartj\/article\/29\/17\/2083\/578019.","DOI":"10.1093\/eurheartj\/ehn346"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2018.02.015","article-title":"Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis","volume":"69","author":"Petta","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_100","unstructured":"(2024, January 25). A Systematic Review and Meta-Analysis of the Therapeutic Equivalence of Statins. Available online: www.hiv-druginteractions.org."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/4\/278\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:18:03Z","timestamp":1760105883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/4\/278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":100,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["pathogens13040278"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13040278","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]}}}